Co-Diagnostics (CODX) Stock Price, News & Analysis

Company Overview

Co-Diagnostics, Inc. is a molecular diagnostics company that develops and commercializes diagnostic tests and laboratory technologies. Based in Salt Lake City, Utah, the company focuses on assays that detect genetic material from infectious diseases and other medical conditions.

The company’s core technology is its CoPrimer platform, which is designed to support the development of molecular tests using specialized primer technology. Products associated with the platform include the Logix Smart line of real-time polymerase chain reaction (PCR) assays, covering applications such as respiratory and other infectious diseases. Co-Diagnostics has also developed tests for conditions including tuberculosis and mosquito-borne diseases, with product availability and regulatory status varying by jurisdiction.

Founded in 2013, Co-Diagnostics serves clinical laboratories, healthcare providers, and distribution partners in the United States and international markets. Its tests and systems may be offered for research, laboratory, or diagnostic use depending on applicable regulatory approvals, and the company continues to expand its molecular testing portfolio through internal development and commercialization partnerships.

Key Stats

• Today's Range: $0.36 to $0.39
• 50-Day Range: $0.35 to $1.26
• 52-Week Range: $0.35 to $13.54
• Volume: 443,400 shs
• Average Volume: 441,666 shs
• Market Capitalization: $3.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Hold

Co-Diagnostics Stock Analysis - MarketRank™

Co-Diagnostics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Co-Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Co-Diagnostics has a consensus price target of $45.00, representing about 12,351.6% upside from its current price of $0.36.

Amount of Analyst Coverage

Co-Diagnostics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Co-Diagnostics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.62% of the float of Co-Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Co-Diagnostics has a short interest ratio ("days to cover") of 1.41, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Co-Diagnostics has recently increased by 56.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Co-Diagnostics does not currently pay a dividend.

Dividend Growth

Co-Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.20

News Sentiment

Co-Diagnostics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Co-Diagnostics this week, compared to 3 articles on an average week.

Search Interest

7 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

MarketBeat Follows

1 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Co-Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.30% of the stock of Co-Diagnostics is held by insiders.

Percentage Held by Institutions

14.99% of the stock of Co-Diagnostics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/04/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CODX
• CIK: 1692415
• Web: www.codiagnostics.com
• Phone: (801) 438-1036
• Fax: N/A
• Employees: 115
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Co-Diagnostics: $45.00
• High Price Target: $45.00
• Low Price Target: $45.00
• Potential Upside/Downside: +12,351.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.90 million
• Net Margins: -6,531.77%
• Pretax Margin: -6,756.77%
• Return on Equity: -210.99%
• Return on Assets: -174.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.81
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: $620 thousand
• Price / Sales: 5.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.14 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 8,820,000
• Free Float: 8,620,000
• Market Cap: $3.19 million
• Optionable: No Data
• Beta: 3.15